Argenx SE (NASDAQ: ARGX) has disclosed Monday that it has entered into an agreement to buy FDA Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals, Inc. for $98 million. This voucher enables its holder to an FDA priority review of A Biologics License Application